These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 17646029)

  • 1. Will longer antimicrobial patents improve global public health?
    Outterson K; Samora JB; Keller-Cuda K
    Lancet Infect Dis; 2007 Aug; 7(8):559-66. PubMed ID: 17646029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Achieving clinical equality in an influenza pandemic: patent realities.
    Kane EM
    Seton Hall Law Rev; 2009; 39(4):1137-72. PubMed ID: 20718133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug resistance, patent resistance: Indian pharmaceuticals and the impact of a new patent regime.
    Halliburton M
    Glob Public Health; 2009; 4(6):515-27. PubMed ID: 19548158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Societal costs versus savings from wild-card patent extension legislation to spur critically needed antibiotic development.
    Spellberg B; Miller LG; Kuo MN; Bradley J; Scheld WM; Edwards JE
    Infection; 2007 Jun; 35(3):167-74. PubMed ID: 17565458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmaceutical patents and some international trade issues: Canada, the United States, and NAFTA.
    Tancer RS
    Clin Ther; 1993; 15(6):1177-84; discussion 1120. PubMed ID: 8111813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. US trade rules seek to balance health and patent protection.
    Wadman M; Cherry M
    Nature; 1999 Dec; 402(6762):567-8. PubMed ID: 10604448
    [No Abstract]   [Full Text] [Related]  

  • 7. The information revolution reaches pharmaceuticals: balancing innovation incentives, cost, and access in the post-genomics era.
    Rai AK
    Univ Ill Law Rev; 2001; 2001(1):173-210. PubMed ID: 16493845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Innovations and intellectual property: the case of genomic patenting.
    Jackson BA
    J Policy Anal Manage; 2003; 22(1):5-25. PubMed ID: 12722760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patents with an "I" = patients.
    Martin AO; Devadas SK
    Ann Health Law; 2009; 18(2):261-80, 7 p. preceding 7. PubMed ID: 21950241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Has the implementation of the TRIPS Agreement in Latin America and the Caribbean produced intellectual property legislation that favours public health?
    Oliveira MA; Bermudez JA; Chaves GC; Velásquez G
    Bull World Health Organ; 2004 Nov; 82(11):815-21. PubMed ID: 15640916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reducing antimicrobial resistance through appropriate antibiotic usage in Singapore.
    Hsu LY; Kwa AL; Lye DC; Chlebicki MP; Tan TY; Ling ML; Wong SY; Goh LG
    Singapore Med J; 2008 Oct; 49(10):749-55. PubMed ID: 18946605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Obtaining, challenging and enforcing pharmaceutical patents under the America Invents Act.
    Genieser LH; McCann CE
    Pharm Pat Anal; 2012 Sep; 1(4):415-26. PubMed ID: 24236880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genomics knowledge and equity: a global public goods perspective of the patent system.
    Smith RD; Thorsteinsdóttir H; Daar AS; Gold ER; Singers PA
    Bull World Health Organ; 2004 May; 82(5):385-9. PubMed ID: 15298230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Access to essential medicines: a Hobbesian social contract approach.
    Ashcroft RE
    Dev World Bioeth; 2005 May; 5(2):121-41. PubMed ID: 15842722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Wild-card patent extensions as a means to incentivize research and development of antibiotics.
    Sonderholm J
    J Law Med Ethics; 2009; 37(2):240-6. PubMed ID: 19493069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimicrobial sensitivity--A natural resource to be protected by a Pigouvian tax?
    Vågsholm I; Höjgård S
    Prev Vet Med; 2010 Aug; 96(1-2):9-18. PubMed ID: 20570379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioterrorism and patent rights: "compulsory licensure" and the case of Cipro.
    Resnik DB; DeVille KA
    Am J Bioeth; 2002; 2(3):29-39. PubMed ID: 12230852
    [No Abstract]   [Full Text] [Related]  

  • 19. Ownership of knowledge--the role of patents in pharmaceutical R&D.
    Correa CM
    Bull World Health Organ; 2004 Oct; 82(10):784-7; discussion 787-90. PubMed ID: 15643801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patent life of antiretroviral drugs approved in the US from 1987 to 2007.
    Rodriguez-Monguio R; Seoane-Vazquez E
    AIDS Care; 2009 Jun; 21(6):760-8. PubMed ID: 19499381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.